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AbstrACt
Objectives We investigated if psychosocial status, 
sociodemographics and smoking status affected non- 
attendance in the control group in the randomised Danish 
Lung Cancer Screening Trial (DLCST).
Design and setting This study was an observational 
study nested in the DLCST. Due to large non- attendance 
in the control group in the second screening round we 
made an additional effort to collect questionnaire data 
from non- attenders in this group in the third screening 
round. We used a condition- specific questionnaire to 
assess psychosocial status. We analysed the differences 
in psychosocial status in the third and preceding rounds 
between non- attenders and attenders in the control 
group in multivariable linear regression models adjusted 
for sociodemographics and smoking status reported at 
baseline. Differences in sociodemographics and smoking 
status were analysed with χ2 tests (categorical variables) 
and t- tests (continuous variables).
Primary outcome measure Primary outcome was 
psychosocial status.
Participants All control persons participating in the third 
screening round in the DLCST were included.
results Non- attenders in the third round had significantly 
worse psychosocial status than attenders in the scales: 
‘behaviour’ 0.77 (99% CI 0.18 to 1.36), ‘self- blame’ 0.59 
(99% CI 0.14 to 1.04), ‘focus on airway symptoms’ 0.22 
(99% CI 0.08 to 0.36), ‘stigmatisation’ 0.51 (99% CI 
0.16 to 0.86), ‘introvert’ 0.56 (99% CI 0.23 to 0.89) and 
‘harms of smoking’ 0.35 (99% CI 0.11 to 0.59). Moreover, 
non- attenders had worse scores than attendees in the 
preceding screening rounds. Non- attenders also reported 
worse sociodemographics at baseline.
Conclusions Non- attenders had a significantly worse 
psychosocial status and worse sociodemographics 
compared with attenders. The results of our study 
contribute with evidence of non- response and attrition 
driven by psychosocial status, which in turn may be 
influenced by the screening intervention itself. This can be 
used to adjust cancer screening trial results for bias due to 
differential non- attendance.
trial registration number  Clinicaltrials. gov Protocol 
Registration System (NCT00496977).
IntrODuCtIOn
Non- attendance may affect trial results and 
introduce bias in randomised controlled 
trials (RCTs).1 2 Non- attendance reduces the 
power of the trial and, if non- attendance 
differs between the randomised groups, 
conventional effect estimates can be biased.2 
While we cannot change the loss of power, 
we may remove bias due to differential non- 
attendance if we know and have measured 
the factors that cause this non- attendance.3 
For some outcome measures, such as disease 
incidence or mortality, non- attendance 
can be partially addressed if data can be 
obtained from national electronic registers. 
However, non- attendance will be larger for 
outcome measures that depend on direct 
data collection such as clinical measurements 
and patient- reported outcome measures 
(PROMs). Moreover, the factors driving 
strengths and limitations of this study
 ► Use of a condition- specific questionnaire with ad-
equate psychometric properties ensured valid 
measures.
 ► Patient- reported data on non- respondents gave valu-
able empirical insight in drivers for non- attendance.
 ► Testing a previously hypothesised model for non- 
attendance empirically is another strength of the 
study.
 ► No comparison between non- attenders in the inter-
vention and the control group was performed.
 ► No longer term follow- up on non- attenders was 
performed.
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Figure 1 Flowchart, the Danish Lung Cancer Screening 
Trial.
non- attendance for these measures may be very hetero-
geneous and may also be driven by the experiences of the 
trial participants in the trial process.
The problems with differential non- attendance may be 
aggravated in trials assessing psychosocial consequences 
of cancer screening as well as other interventions where it 
is impossible to blind participants to allocation. Notably, a 
control group not offered screening may be less inclined 
to return questionnaires enquiring into their experiences 
with a potentially beneficial intervention they did not 
receive. However, the psychosocial dimensions of non- 
attendance and potential consequences of these in lung 
cancer screening trials are only partially researched.4–7 
Since cancer screening trials are investigating potentially 
life- threatening diseases there may be emotional drivers of 
non- attendance, not typical for trials in general. Hence, it 
is of interest to know which factors drive non- attendance 
in PROMs in cancer screening trials as these data are to 
be collected in these trials and then used in adjusting for 
differential non- attendance.
The Danish Lung Cancer Screening Trial (DLCST) was 
an RCT including five annual screening rounds of low- dose 
chest CT plus clinical examinations in the intervention 
group compared with annual clinical examinations only 
in the control group.8 Furthermore, all the participants 
were asked to complete a condition- specific questionnaire, 
measuring psychosocial consequences of lung cancer 
screening at these annual clinical assessments.9 The results 
showed that people experienced negative psychosocial 
consequences merely by participating in the trial, and that 
negative consequences were higher for participants allo-
cated to the control group.7 10 A large number of control 
persons did not attend the second annual examination 
(n=513, 26.1%), while the non- attendance rate in the 
intervention group was low (n=71, 3.5%) (figure 1). To 
adjust for this differential non- attendance, inverse prob-
ability weighting was used.7 In this method, the observed 
outcomes are weighted with the inverse of the probability 
of being non missing.3 We hypothesised that these proba-
bilities were adequately estimated from sociodemographic 
profile including smoking status, randomisation group and 
psychosocial status in previous rounds.7 11–13
If these hypotheses were confirmed, then these factors 
would explain the witnessed difference in attendance 
between the trial groups and could be used to render 
them comparable. Analysed without such adjustments 
the assessment of the trial groups, and thereby the means 
of the scores from the responses to the questionnaire 
from the remaining trial participants would no longer 
be comparable.14 Hence, the assessment of psychosocial 
harms of lung cancer screening could be biased.
Therefore, the overall aim of this study was to empir-
ically assess whether control participants who did not 
attend the annual clinical examination had different 
psychosocial profiles compared with control participants 
who attended the annual clinical examination.
MAterIAls AnD MethODs
study design and population
The design and study population of DLCST have been 
described in detail previously.7 8 Briefly, the DLCST was an 
RCT, conducted at the Copenhagen University Hospital 
Gentofte in Denmark from October 2004 to March 2010. 
Heavy current and former smokers (at least 20 pack- years), 
aged 50–70 years old, were randomised to either five 
rounds of screening with low- dose CT scans including clin-
ical examinations (n=2052) or five clinical examinations 
only (n=2052). In the enrolment visit, participants provided 
sociodemographic data, lifestyle and health information 
(including smoking status), completed a questionnaire on 
their psychosocial status and underwent spirometry. Partic-
ipants randomised to screening also had a low- dose chest 
CT scan within 1 month of randomisation. In the following 
screening rounds, participants in the screened and control 
groups were invited to a visit in the screening clinic where 
lung function tests were performed, and questionnaires 
concerning health, lifestyle, smoking habits and psycho-
social status were completed and lung function tests were 
performed. Participants randomised to screening also 
received a low- dose chest CT scan.
This study is an observational study nested in the 
DLCST. During the second screening round, the steering 
committee noted that a large number of control partic-
ipants did not attend the screening clinic visit when 
compared with the number of screened participants. 
Thus, the committee decided to make additional efforts 
to collect questionnaire data for non- attenders in the 
control group in the third screening round to perform 
posthoc analyses on whether psychosocial status was an 
influencing factor (figure 2).
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Figure 2 Flowchart, present study.
During the third round, participants in the control 
group who did not attend the annual examination were 
contacted by phone, and part 1 of the questionnaire was 
sent with a postage paid envelope to those who gave their 
oral consent. The data were used to supplement the data 
collected on site at the screening clinic.7 This yielded 
three groups within the control group, denoting the 
extent of response to the clinical examination and the 
questionnaire defined as:
1. Attenders: participants who attended the third screen-
ing round.
2. Non- attenders:
a. Respondents: participants who did not attend the 
annual examination but completed and returned 
the Consequences in Screening in Lung Cancer 
(COS- LC) after the phone interview.
b. Non- respondents: participants who did not attend 
the annual examination and did not complete the 
COS- LC.
Primary outcome was psychosocial status measured with 
the COS- LC questionnaire.9 Part 1 of COS- LC comprised 
nine scales measuring various aspects of consequences 
of screening; a second part of COS- LC addressed the 
screening outcome and was therefore not applicable 
to the present analysis. Moreover, the primary part of 
COS- LC included four core scales: ‘anxiety’, ‘behaviour’, 
‘dejection’ and ‘sleep’ that are not lung cancer specific. 
These scales have originally been developed from a breast 
cancer screening assessment instrument.15 Additionally 
COS- LC comprised five lung cancer- specific scales: ‘self- 
blame’, ‘focus on airway symptoms’, ‘stigmatisation’, 
‘introvert’ and ‘harm of smoking’, which were developed 
from focus groups and other screening assessment instru-
ments during the first DLCST screening round.9 15 There-
fore, only the core scales were used in the first round, 
while in the following four screening rounds, both the 
core scales and the lung cancer- specific scales were used 
to assess psychosocial status.9
statistics
Covariates
Sociodemographic characteristics were defined by: social 
class (I highest social class to V lowest social class), school 
and vocational education (from 9 years of elementary 
school to a university education), employment status, 
living alone, smoking status (current or former smoker), 
smoking history (pack- years), motivation for smoking 
cessation (from very strong to no wish to quit) and 
Charlson Comorbidity Index (CCI). Furthermore, we 
adjusted for region of residence (Denmark is divided into 
five health administrative regions).
Statistical analyses
We performed three different analyses:
1. Analyses of differences in psychosocial status in the 
third round between attenders and non- attenders 
respondents.
2. Analyses of differences in psychosocial status in the sec-
ond round between attenders, non- attenders respon-
dents and non- attenders non- respondents.
3. Analyses of differences in psychosocial status in the 
first round, between attenders, non- attenders respon-
dents and non- attenders non- respondents.
Covariates at the first screening round were compared 
between attenders and non- attenders by χ2 tests (categor-
ical characteristics) and t- tests (continuous characteris-
tics). Analyses of psychosocial status at various points in 
the follow- up were performed in linear regression models 
both unadjusted and in multivariable models adjusted for 
sex, age, region of residence, social class, living alone, 
smoking status, pack- years, motivation for smoking cessa-
tion and CCI. To adjust for multiple testing, we used the 
Benjamini- Hochberg procedure and the False Discovery 
Rate (FDR) was set to 5%.16 All analyses were performed 
with SAS V.9.4 (SAS Institute).
Patient and public involvement
Patients and public were not involved in the design of the 
study.
results
The inclusion process and participation rate of the 
DLCST are illustrated in figure 1. The participation rate 
in the control group fell from 73.9% in the second round 
to 57.5% in the fourth round. The participation rate 
increased in the fifth, final, round (68.9%).
Figure 2 depicts the inclusion process of the present 
study and showed a dropout rate of 29.6% (n=607) in the 
third screening round with a higher distribution of non- 
attenders non- respondents (16.9% n=347) compared 
with non- attenders respondents (12.7% n=260).
In the first screening round we compared differences 
in sociodemographic characteristics in the two overar-
ching groups (attenders, non- attenders) (table 1).
There was a significant difference between the study 
groups for social class with more non- attenders in the 
lowest social class (V) and a greater number of attenders 
in the highest social classes (I–II).
Moreover, non- attenders had a significantly higher CCI 
score indicating that they had more severe or a greater 
number of co- occurring conditions than attenders. They 
were also to a greater extent living alone. Furthermore, 
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Table 1 Sociodemographics
Covariates
Missing observations, total Attenders n=1388 Non- attenders n=607
P value*n n (%)† n(%)†
Sex 0     0.0963
Male   773 (55.7) 313 (51.6)
Female   615 (44.3) 294 (48.4)
Age, mean (SD) 0 57.4 (4.7) 56.9 (4.9) 0.0538
Social class 12     0.0079
I (highest social status)   103 (7.5) 35 (5.8)
II   296 (21.4) 100 (16.6)
III   256 (18.5) 114 (18.9)
IV   375 (27.2) 161 (26.7)
V (lowest social status)   168 (12.2) 107 (17.7)
Employed, social class uncertain   112 (8.1) 49 (8.1)
Outside the labour market   70 (5.1) 37 (6.1)
School education 5     0.7765
9 years of elementary school   473 (34.2) 220 (36.3)
10 years of elementary school   541 (39.1) 231 (38.1)
3 years of upper secondary school   363 (26.2) 153 (25.3)
Other   7 (0.5) 2 (0.3)
Vocational education 4     0.1267
None   124 (9.0) 72 (11.9)
Semiskilled worker   17 (1.2) 10 (1.7)
Vocational training   491 (35.4) 212 (35.0)
Short further education   142 (10.2) 48 (7.9)
Middle- range training   357 (25.8) 167 (27.6)
Long further education   153 (11.0) 64 (10.6)
Other   102 (7.4) 32 (5.3)
Employment status 6     0.8394
Employed   901 (65.2) 387 (63.9)
Studying   8 (0.6) 4 (0.7)
Job seeking   67 (4.8) 35 (5.8)
Retired   407 (29.4) 180 (29.7)
CCI, mean (SD)   0.26 (0.73) 0.31 (0.83) 0.0062
Living alone 17     0.0057
No   1011 (73.5) 405 (67.3)
Yes   365 (26.5) 197 (32.7)
Smoking status 0     0.0122
Current smoker   1046 (75.4) 489 (80.6)
Former smoker   342 (24.6) 118 (19.4)
Pack- years, mean (SD) 4 35.7 (13.7) 35.8 (12.3) 0.4207
Motivation for smoking cessation 30     0.0540
Very strong   141 (10.3) 74 (12.4)
Strong   324 (23.7) 166 (27.8)
Weak   331 (24.2) 144 (24.8)
Very weak   116 (8.5) 42 (7.0)
No wish to quit   113 (8.3) 54 (9.0)
Current non- smoker   342 (25.0) 118 (19.7)
*Benjamini- Hochberg rejects all p values above 0.0321 to control the FDR at 0.05.
†Except when indicated in the leftmost column that the mean and SD are listed.
CCI, Charlson Comorbidity Index; FDR, False Discovery Rate.
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Table 2 Differences in psychosocial status in the third screening round
Range of 
values
Responding 
rate per item 
n/n
Attenders 
n=1388
mean (SD)
Non- attenders- 
respondents 
n=260
mean (SD) P value*
Difference in scores 
between the two groups 
mean (99% CI)†
P value 
adjusted*
COS scales
  Anxiety 0–18 1349/249 1.7 (2.8) 2.1 (3.2) 0.0441 0.38 (-0.13 to 0.89) 0.0548
  Behaviour 0–21 1343/246 2.1 (3.1) 2.9 (3.8) <0.001 0.77 (0.18 to 1.36) <0.001
  Dejection 0–18 1354/255 1.9 (3.0) 2.4 (3.5) 0.013 0.49 (-0.06 to 1.04) 0.0225
  Sleep 0–12 1357/252 1.9 (2.6) 2.3 (3.0) 0.041 0.35 (-0.12 to 0.82) 0.0599
COS- LC scales
  Self- blame 0–15 1356/234 2.2 (2.8) 3.1 (3.8) <0.001 0.59 (0.14 to 1.04) <0.001
  Focus on airway 
symptoms
0–24 1363/239 0.3 (0.8) 0.6 (1.0) <0.001 0.22 (0.08 to 0.36) <0.001
  Stigmatisation 0–12 1361/241 1.5 (1.9) 2.1 (2.4) <0.001 0.51 (0.16 to 0.86) <0.001
  Introvert 0–18 1361/243 1.3 (1.8) 1.8 (2.2) <0.001 0.56 (0.23 to 0.89) <0.001
  Harms of smoking 0–6 1356/248 0.9 (1.2) 1.3 (1.6) <0.001 0.35 (0.11 to 0.59) <0.001
*Benjamini- Hochberg rejects all p values above 0.0321 to control the FDR at 0.05.
†A positive value of the difference indicates that the persons that were interviewed by phone and later returned COS- LC had on average 
higher scores, that is, more negative outcomes (eg, higher anxiety) than the persons that showed up and completed the COS- LC on 
site. The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack- years, motivation for 
smoking cessation and CCI. The continuous values variables (age and pack- years) are included as a quadratic function as to allow for 
possible non- linear effects.
CCI, Charlson Comorbidity Index; COS, Consequences in Screening; COS- LC, Consequences in Screening in Lung Cancer; FDR, False 
Discovery Rate.
there were significantly more current smokers and a non- 
significant trend of a higher wish to quit smoking in the 
group of non- attenders compared with attenders.
The results of the third screening round are listed in 
table 2.
In the core questionnaire Consequences of Screening 
(COS), non- attenders respondents had a statistically 
significant higher (worse) score than attenders in the 
scales ‘behaviour’ and ‘dejection’. These effects were 
still present when adjusting for covariates. Moreover, 
there was a non- significant trend of worse scores in all 
COS scales among non- attenders respondents. In the 
lung cancer- specific part of the COS- LC, non- attenders 
respondents had statistically significantly higher scores in 
all scales both crude and adjusted.
Table 3 shows differences in psychosocial status between 
all three subgroups in the second screening round.
Non- attenders had significantly worse crude scores 
compared with attenders in all the COS scales. When 
adjusting for covariates the difference in scores was still 
significant in the three scales ‘anxiety’, ‘dejection’ and 
‘sleep’. In the lung cancer- specific part, the crude and 
adjusted ‘self- blame’ and ‘introvert’ scale scores were 
significantly worse for non- attenders. The difference in 
‘stigmatisation’ scale score was statistically significant in 
the unadjusted analyses but disappeared in the adjusted 
analyses.
The differences in psychosocial status in the first 
screening round between attenders, non- attenders 
respondents and non- attenders non- responders showed a 
statistically significant worse unadjusted score in all COS 
scales for the two non- attenders subgroups (table 4). That 
effect disappeared in all but one scale, ‘anxiety’ when 
adjusting for covariates.
DIsCussIOn
The present study showed considerable non- attendance 
in the control group of the DLCST. Data in the control 
group were not missing at random. Non- attenders had 
less favourable baseline sociodemographic profile when 
compared with attenders. More importantly, individ-
uals who did not attend their annual clinical workup 
had worse psychosocial status than the individuals who 
attended the clinic in the previous rounds. This can be 
used to adjust for differential non- attendance. Further-
more, these individuals also had worse psychosocial status 
during their missed round (assessed in the present study 
in the third round). This cannot be used to adjust differ-
ential non- attendance because this information is gener-
ally not available but proves the concept.
The use of a condition- specific questionnaire is a strength 
of the study. Previous research has demonstrated that 
condition- specific questionnaires are superior to generic 
questionnaires when measuring psychosocial consequences 
in cancer screening settings.17 Furthermore, we used an 
appropriate longitudinal design, that is, we collected data at 
the same time points for both attenders and non- attenders 
at various times in the study, as well as we measured psycho-
social status in both groups at baseline.18
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Table 3 Differences in psychosocial status in the second screening round
Range of 
values
Responding 
rate per item 
n/n/n
Attenders 
n=1388
Non- attenders 
respondents 
n=260
Non- attenders non- 
respondents n=347 P value*
P value 
adjusted†*
COS scales, mean (SD)
  Anxiety 0–18 1201/117/89 1.6 (2.7) 2.0 (3.0) 2.6 (3.8) 0.003 0.018
  Behaviour 0–21 1195/114/88 1.9 (2.9) 2.4 (3.3) 2.8 (4.0) 0.012 0.071
  Dejection 0–18 1217/117/87 1.8 (2.8) 2.3 (3.3) 3.0 (4.0) <0.001 <0.001
  Sleep 0–12 1220/116/88 1.7 (2.5) 2.3 (2.9) 2.6 (3.2) <0.001 0.002
COS- LC scales, mean (SD)
  Self- blame 0–15 1210/118/88 1.7 (2.3) 2.1 (2.4) 2.6 (3.0) <0.001 0.005
  Focus on airway 
symptoms
0–24 1226/118/90 0.4 (0.8) 0.4 (0.8) 0.5 (0.9) 0.408 0.579
  Stigmatisation 0–12 1225/121/90 1.5 (1.9) 1.8 (2.1) 2.1 (2.4) 0.028 0.146
  Introvert 0–18 1223/116/90 1.3 (1.8) 1.8 (2.0) 1.4 (1.8) 0.012 0.021
  Harms of smoking 0–6 1232/118/89 1.1 (1.3) 1.3 (1.3) 1.2 (1.4) 0.134 0.422
*Benjamini- Hochberg rejects all p values above 0.0321 to control the FDR at 0.05.
†A test for differences between the three groups adjusted for sex, age, region of residence, social group, living alone, smoking status, 
pack- years, motivation for smoking cessation and the CCI. The continuous values variables (age and pack- years) are included as a 
quadratic function as to allow for possible non- linear effects.
CCI, Charlson Comorbidity Index; COS, Consequences in Screening; COS- LC, Consequences in Screening in Lung Cancer; FDR, False 
Discovery Rate.
Table 4 Differences in psychosocial status in the first screening round
Range of 
values
Responding 
rate per item 
n/n/n
Attenders 
n=1388
mean (SD)
Non- attenders 
respondents 
n=260
mean (SD)
Non- attenders 
non- respondents 
n=347
mean (SD) P value*
P value 
adjusted†*
COS scales
  Anxiety 0–18 1353/253/334 1.46 (2.16) 1.75 (2.54) 2.11 (2.66) <0.001 0.0028
  Behaviour 0–21 1365/257/340 0.75 (1.89) 1.05 (2.44) 1.04 (2.43) 0.0134 0.0976
  Dejection 0–18 1372/257/339 1.25 (2.05) 1.54 (2.48) 1.68 (2.33) 0.0018 0.0512
  Sleep 0–12 1368/253/344 0.62 (1.64) 0.86 (1.98) 0.90 (1.86) 0.0072 0.0530
*Benjamini- Hochberg rejects all p values above 0.0321 to control the FDR at 0.05.
†The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack- years, motivation for smoking 
cessation and CCI. The continuous values variables (age and pack- years) are included as a quadratic function as to allow for possible non- 
linear effects.
CCI, Charlson Comorbidity Index;; COS, Consequences in Screening; FDR, False Discovery Rate.
A limitation of the study is that we did not collect 
psychosocial outcomes of non- attenders in the interven-
tion group. This study was designed to gain knowledge of 
factors motivating such a large drop in participation in 
the control group. In hindsight, data on non- attenders in 
the screened group could further help us understand the 
reasons for differential non- response.
The distribution of psychosocial outcomes was left 
skewed (tables 2–4). To assure that the conclusions were 
not affected by this skewness, we repeated the analyses 
on log- transformed outcomes. The results of these sensi-
tivity analyses reached conclusions similar to the original 
conclusions.
In addition to the DLCST, two other trials assessed 
psychosocial consequences in lung cancer screening 
with low- dose CT.6 19 Participants in the Dutch- Belgian 
Randomised Lung Cancer Screening trial (Dutch 
acronym: the NELSONstudy) were invited to complete 
questionnaires at baseline and at the second round 
of screening (2 years after baseline screening). Partic-
ipants in the UK Lung Cancer Screening Trial (UKLS) 
completed a questionnaire at baseline, 2 weeks after 
randomisation/CT scan and 10–29 months after base-
line. Unlike the DLCST, in these two trials, the control 
group were not invited to an annual visit at the screening 
clinic. Although there were some differences in study 
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design, non- response rates in the control groups in these 
three trials were similar, and in all three trials there was 
differential non- response between the intervention and 
control group. Differences between attenders and non- 
attenders were reported in the UKLS trial. As in the 
DLCST, non- attenders had worse sociodemographic 
profile that is, lower social class, and they were more likely 
single, younger and current smokers compared with 
attenders. However, these were pooled estimates for both 
the screening group and the control group.
In individuals diagnosed with cancer, anxiety and worse 
health- related quality of life have been associated with 
dropout, which is consistent with our findings.20 Since 
non- attenders in our study experienced a higher level 
of anxiety than attenders in the first screening round 
(ie, baseline), this could have been the motivation for 
attending the trial; to get reassured of being healthy.21 
Therefore, randomisation to the control group may have 
caused disappointment but also attention drawn to not 
being part of a possibly beneficial intervention.22 For 
example, the secretary in the screening clinic received 
calls from participants randomised to the control group 
expressing their disappointment of not being screened. 
Furthermore, the trial put focus on the harms of smoking, 
which could have increased the anxiety and fear of 
disease in this subgroup even more, which may have been 
a reason for subsequent non- attendance. Finally, missing 
data on psychosocial status in a previous round may also 
have been a predictor for non- attendance in the next 
screening round, which was not the scope of this study.
Low social status, younger age and current smoking 
status have previously been seen among dropouts and non- 
respondents in lung health studies.23–26 A systematic review 
reporting dropout from longitudinal studies in elderly 
concluded that higher age and declining health were high 
predictors of dropout. The latter is in agreement with our 
findings, although higher age is in contrast to our findings.27
To our knowledge, this is the first cancer screening study 
testing hypotheses on reasons for differential non- response 
empirically. The results of this study confirmed the hypoth-
eses we made in our previous study, using inverse proba-
bility weighting to adjust for differential non- response.3 7 28 
More importantly, the results of the two other lung cancer 
screening trials investigating dropout are consistent with 
ours. Hence, it is plausible that our results are generalisable 
to other cancer screening trials as well.
Therefore, future cancer screening trials should 
concurrently assess psychosocial status during the trial to 
be able to assess the psychosocial effect of screening and 
to use this information to adjust any effect in the trial for 
bias due to differential non- attendance.
COnClusIOns
In conclusion, non- attenders in the control group in the 
DLCST had a worse psychosocial status and a less favour-
able sociodemographic profile than attenders.
The results of our study contribute with evidence of 
non- response driven by psychosocial status, which in turn 
may be influenced by the screening intervention itself. 
This can be used to adjust cancer screening trial results 
for bias due to differential attendance.
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